Ananda Developments - Result of AGM
Announcement provided by
Ananda Developments Plc · ANA24/08/2023 14:28
24 August 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Result of Annual General Meeting
Ananda Developments plc (AQSE: ANA) is pleased to announce that at the Annual General Meeting of the Company held earlier today all resolutions were duly passed by shareholders.
Proxy votes were received as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes total |
Votes withheld |
|
Resolution 1 |
278,538,686 |
99.99% |
26,192 |
0.01% |
278,564,878 |
6,976 |
|
Resolution 2 |
278,256,362 |
99.98% |
46,725 |
0.02% |
278,303,087 |
268,767 |
|
Resolution 3 |
278,276,792 |
99.99% |
26,295 |
0.01% |
278,303,087 |
268,767 |
|
Resolution 4 |
278,256,362 |
99.98% |
46,725 |
0.02% |
278,303,087 |
268,767 |
|
Resolution 5 |
278,256,362 |
99.98% |
46,725 |
0.02% |
278,303,087 |
268,767 |
|
Resolution 6 |
278,538,583 |
99.99% |
26,295 |
0.01% |
278,564,878 |
6,976 |
|
Resolution 7 |
278,276,792 |
99.99% |
26,295 |
0.01% |
278,303,087 |
268,767 |
|
Resolution 8 |
278,276,792 |
99.99% |
26,295 |
0.01% |
278,303,087 |
268,767 |
|
Resolution 9 |
278,291,237 |
99.99% |
26,295 |
0.01% |
278,317,532 |
254,322 |
|
Resolution 10 |
278,276,792 |
99.98% |
48,748 |
0.02% |
278,325,540 |
254,322 |
|
Resolution 11 |
278,256,362 |
99.98% |
48,748 |
0.02% |
278,305,110 |
274,752 |
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
|
ANANDA DEVELOPMENTS PLC |
+44 (0)7463 686 497 |
|
|
ir@anandadevelopments.com |
|
Chief Executive Officer |
|
|
Melissa Sturgess |
|
|
|
|
|
Finance Director |
|
|
Jeremy Sturgess-Smith |
|
|
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
+44 (0)20 3470 0470 |
|
|
|
|
Corporate Finance |
|
|
Richard Morrison |
|
|
Harry Davies-Ball |
|
|
|
|
|
Corporate Broking |
|
|
Abigail Wayne |
|
|
Rob Rees |
|
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
For more information, please visit: https://anandadevelopments.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.